Tesa-IPA-CJC (No-Dac) 12mg Research Blend (Tesamorelin 6mg / CJC-1295 No-DAC 3mg / Ipamorelin 3mg)
Lyophilized Format • ≥99% HPLC Purity • Ships in 1–2 Business Days • U.S. Warehouses
Tesa-IPA-CJC (No-Dac) is a 12mg growth hormone secretagogue research blend combining Tesamorelin (6mg), CJC-1295 without DAC (3mg), and Ipamorelin (3mg) per vial — three peptides studied for their complementary roles in the GHRH/ghrelin signaling axis. Tesamorelin is a stabilized 44 amino acid analog of growth hormone-releasing hormone (GHRH). CJC-1295 (No-DAC), also known as Mod GRF 1-29, is a shorter-acting GHRH analog lacking the Drug Affinity Complex modification, giving it a brief half-life relative to its DAC-conjugated counterpart. Ipamorelin is a selective pentapeptide ghrelin receptor agonist studied for growth hormone secretagogue activity with minimal reported effect on cortisol or prolactin in preclinical models. This blend combines two GHRH-pathway analogs with a ghrelin-receptor secretagogue in a single lyophilized vial for laboratories studying combinatorial growth hormone pulsatility and secretagogue receptor pathway biology. Each vial is independently verified to ≥99% HPLC purity with a Certificate of Analysis available on request. For laboratory research use only.
Compound Specifications
| Blend Name | Tesa-IPA-CJC (No-Dac) 12mg |
| Classification | Multi-component growth hormone secretagogue research blend |
| Component 1 | Tesamorelin — 6mg (GHRH analog, 44 amino acids) |
| Component 2 | CJC-1295 (No-DAC / Mod GRF 1-29) — 3mg (short-acting GHRH analog, 29 amino acids) |
| Component 3 | Ipamorelin — 3mg (selective ghrelin receptor agonist, 5 amino acids) |
| Total Vial Content | 12mg combined |
| Studied Pathways | GHRH receptor signaling, ghrelin/GHS-R1a activation, pulsatile GH secretion |
| Form | Lyophilized powder |
| Appearance | White to off-white powder |
| Purity | ≥99% (HPLC verified, per component) |
| Storage | -20°C lyophilized; 2–8°C after reconstitution |
| Synonyms | Tesa/Ipa/CJC blend, Tesamorelin-Ipamorelin-CJC1295(No-DAC) stack, GHRH/GHRP research blend |
Why Research Laboratories Select Tesa-IPA-CJC (No-Dac)
Tesa-IPA-CJC (No-Dac) consolidates two structurally distinct GHRH analogs and a selective ghrelin receptor agonist into one lyophilized vial, giving laboratories a single-source reagent for investigating combinatorial growth hormone secretagogue signaling without independently sourcing and reconstituting three separate peptides.
- Combines two GHRH-pathway analogs (Tesamorelin, CJC-1295 No-DAC) with a selective ghrelin receptor agonist (Ipamorelin)
- Each component has independent, well-characterized receptor pharmacology in the peer-reviewed literature
- No-DAC formulation of CJC-1295 avoids the extended albumin-binding half-life of the DAC-conjugated variant, useful for research designs requiring shorter-acting GHRH exposure
- Useful reference blend for comparative GHRH receptor / GHS-R1a signaling and pulsatile secretion research
- Lyophilized format ensures stability and reproducibility across experimental runs
- Batch and lot identifiers on all labeling for full laboratory documentation compliance
Research Background
Each component of Tesa-IPA-CJC (No-Dac) has an independent research literature base. Tesamorelin has been studied extensively as a GHRH analog, including FDA-reviewed clinical data in the context of HIV-associated lipodystrophy. CJC-1295 has been studied in both DAC and non-DAC forms for its GHRH receptor agonism and growth hormone pulse amplitude effects in preclinical models (Teichman et al., 2006, Journal of Clinical Endocrinology & Metabolism). Ipamorelin has been studied as a selective ghrelin receptor (GHS-R1a) agonist with a preclinical profile suggesting reduced off-target effects on cortisol and prolactin compared to earlier growth hormone-releasing peptides (Raun et al., 1998, European Journal of Endocrinology). Note: the specific three-component combination in this blend has not itself been the subject of published clinical or preclinical trials — it is offered as a research convenience product, and any additive or synergistic pathway interactions between the three components should be treated as an open research question rather than an established finding. Tesa-IPA-CJC (No-Dac) is not FDA approved for any indication. All information provided here is for educational and reference purposes only and does not constitute medical or clinical guidance.
Shipping & Fulfillment
- Ships from U.S. warehouses — Florida, North Carolina, and California
- Overnight and 2-day shipping available at checkout
- Same-day processing on orders placed before 3:30 PM ET
- Discreet packaging with full tracking provided
- Bulk research orders welcome — contact us for volume pricing
Storage & Handling
- Store lyophilized peptide at -20°C away from light and moisture
- After reconstitution store at 2–8°C and use within 7 days
- Avoid repeated freeze-thaw cycles to maintain peptide integrity
- Handle using appropriate laboratory safety protocols
- Keep containers sealed when not in use
Frequently Asked Questions
What is Tesa-IPA-CJC (No-Dac)?
Tesa-IPA-CJC (No-Dac) is a 12mg growth hormone secretagogue research blend combining Tesamorelin (6mg), CJC-1295 without DAC (3mg), and Ipamorelin (3mg) in a single lyophilized vial, intended for laboratory research into GHRH and ghrelin receptor signaling pathways.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC includes a Drug Affinity Complex that binds serum albumin, extending its half-life to several days in research models. CJC-1295 without DAC (Mod GRF 1-29) lacks this modification and is cleared much more quickly, giving researchers a shorter-acting GHRH analog for comparative pharmacokinetic study designs.
What is Ipamorelin?
Ipamorelin is a selective pentapeptide agonist of the ghrelin receptor (GHS-R1a), studied for growth hormone secretagogue activity with a preclinical profile suggesting minimal impact on cortisol, prolactin, or appetite signaling relative to earlier-generation GHRPs.
Has this specific three-compound blend been studied together?
No. Each component has independent research literature, but the combination itself has not been the subject of published trials. Any combined or synergistic effects should be treated as an open research question.
What purity is Tesa-IPA-CJC (No-Dac)?
Each component is independently verified to ≥99% HPLC purity. A Certificate of Analysis is available for each lot.
How fast does Nextday Peptides ship?
We ship from U.S. warehouses in Florida, North Carolina, and California. Overnight and 2-day shipping options are available. Orders placed before 3:30 PM ET are processed same day.
Are bulk orders available?
Yes. We accommodate bulk research orders. Contact us directly for volume pricing and availability.
Is this product approved for medical use?
No. Tesa-IPA-CJC (No-Dac) is not approved by the FDA for any indication. This product is for laboratory research use only and is not intended for diagnostic, therapeutic, or clinical applications of any kind.
What other compounds does Nextday Peptides carry?
We also carry Retatrutide GLP-3, Tirzepatide GLP-2T, Semaglutide GLP-1, and MOTS-c. View our full research compounds catalog.
For Research Use Only — Not for human or veterinary consumption • Not FDA approved for any indication • Supplied by Nextday Peptides for controlled in-vitro laboratory research use only